These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 22011763)

  • 1. Donor graft steatosis influences immunity to hepatitis C virus and allograft outcome after liver transplantation.
    Subramanian V; Seetharam AB; Vachharajani N; Tiriveedhi V; Angaswamy N; Ramachandran S; Crippin JS; Shenoy S; Chapman WC; Mohanakumar T; Anderson CD
    Transplantation; 2011 Dec; 92(11):1259-68. PubMed ID: 22011763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of HCV-specific CD4+Th17 immunity in recurrent hepatitis C-induced liver allograft fibrosis.
    Basha HI; Subramanian V; Seetharam A; Nath DS; Ramachandran S; Anderson CD; Shenoy S; Chapman WC; Crippin JS; Mohanakumar T
    Am J Transplant; 2011 Apr; 11(4):775-85. PubMed ID: 21446979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of donor graft steatosis on overall outcome and viral recurrence after liver transplantation for hepatitis C virus cirrhosis.
    Briceño J; Ciria R; Pleguezuelo M; de la Mata M; Muntané J; Naranjo A; Sánchez-Hidalgo J; Marchal T; Rufián S; López-Cillero P
    Liver Transpl; 2009 Jan; 15(1):37-48. PubMed ID: 19109846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Temporal association between increased virus-specific Th17 response and spontaneous recovery from recurrent hepatitis C in a liver transplant recipient.
    Seetharam AB; Borg BB; Subramanian V; Chapman WC; Crippin JS; Mohanakumar T
    Transplantation; 2011 Dec; 92(12):1364-70. PubMed ID: 22082818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Humoral immune response to hepatitis C after liver transplantation: assessment of a new recombinant immunoblot assay.
    Rosen HR; Gretch D; Kaufman E; Quan S
    Am J Gastroenterol; 2000 Aug; 95(8):2035-9. PubMed ID: 10950054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Donor livers with steatosis are safe to use in hepatitis C virus-positive recipients.
    Burra P; Loreno M; Russo FP; Germani G; Galligioni A; Senzolo M; Cillo U; Zanus G; Fagiuoli S; Rugge M
    Liver Transpl; 2009 Jun; 15(6):619-28. PubMed ID: 19479805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mild donor liver steatosis has no impact on hepatitis C virus fibrosis progression following liver transplantation.
    Botha JF; Thompson E; Gilroy R; Grant WJ; Mukherjee S; Lyden ER; Fox IJ; Sudan DL; Shaw BW; Langnas AN
    Liver Int; 2007 Aug; 27(6):758-63. PubMed ID: 17617118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated soluble CD30 characterizes patients with hepatitis C virus-induced liver allograft cirrhosis.
    Bharat A; Narayanan K; Golocheikine A; Steward N; Crippin J; Lisker-Melman M; Shenoy S; Lowell J; Chapman WC; Mohanakumar T
    Transplantation; 2007 Dec; 84(12):1704-7. PubMed ID: 18165785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perioperative blood transfusion affects hepatitis C virus (HCV)-specific immune responses and outcome following liver transplantation in HCV-infected patients.
    Subramanian V; Bharat A; Vachharajani N; Crippin J; Shenoy S; Mohanakumar T; Chapman WC
    HPB (Oxford); 2014 Mar; 16(3):282-94. PubMed ID: 23869514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical experience gained from the use of 120 steatotic donor livers for orthotopic liver transplantation.
    Verran D; Kusyk T; Painter D; Fisher J; Koorey D; Strasser S; Stewart G; McCaughan G
    Liver Transpl; 2003 May; 9(5):500-5. PubMed ID: 12740794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C virus-specific T-cell response correlates with hepatitis activity and donor IL28B genotype early after liver transplantation.
    Tsuzaki R; Takaki A; Yagi T; Ikeda F; Koike K; Iwasaki Y; Shiraha H; Miyake Y; Sadamori H; Shinoura S; Umeda Y; Yoshida R; Nobuoka D; Utsumi M; Nakayama E; Fujiwara T; Yamamoto K
    Acta Med Okayama; 2014; 68(5):291-302. PubMed ID: 25338486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathological Roles of Interleukin-22 in the Development of Recurrent Hepatitis C after Liver Transplantation.
    Gao Y; Ren H; Meng F; Li J; Cheung E; Li H; Zhao J; Liu H; Liu Z; Zhang M
    PLoS One; 2016; 11(4):e0154419. PubMed ID: 27123854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Excess body weight, liver steatosis, and early fibrosis progression due to hepatitis C recurrence after liver transplantation.
    Toniutto P; Fabris C; Avellini C; Minisini R; Bitetto D; Rossi E; Smirne C; Pirisi M
    World J Gastroenterol; 2005 Oct; 11(38):5944-50. PubMed ID: 16273604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation.
    Rosen HR; Shackleton CR; Higa L; Gralnek IM; Farmer DA; McDiarmid SV; Holt C; Lewin KJ; Busuttil RW; Martin P
    Am J Gastroenterol; 1997 Sep; 92(9):1453-7. PubMed ID: 9317061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic steatosis: a specific sign of hepatitis C reinfection after liver transplantation.
    Baiocchi L; Tisone G; Palmieri G; Rapicetta M; Pisani F; Orlando G; Casciani CU; Angelico M
    Liver Transpl Surg; 1998 Nov; 4(6):441-7. PubMed ID: 9791153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful treatment of fibrosing cholestatic hepatitis after liver transplantation.
    Cimsit B; Assis D; Caldwell C; Arvelakis A; Taddei T; Kulkarni S; Schilsky M; Emre S
    Transplant Proc; 2011 Apr; 43(3):905-8. PubMed ID: 21486625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of severely steatotic grafts in liver transplantation: a matched case-control study.
    McCormack L; Petrowsky H; Jochum W; Mullhaupt B; Weber M; Clavien PA
    Ann Surg; 2007 Dec; 246(6):940-6; discussion 946-8. PubMed ID: 18043095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis C recurrence is not associated with allograft steatosis within the first year after liver transplantation.
    Machicao VI; Krishna M; Bonatti H; Aqel BA; Nguyen JH; Weigand SD; Rosser BG; Hughes C; Dickson RC
    Liver Transpl; 2004 May; 10(5):599-606. PubMed ID: 15108251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recurrent hepatitis C virus infection after liver transplantation--long-term follow-up with respect to the HCV genotypes/subtypes.
    Arnold JC; Töx U; Goeser T; Otto G; Müller HM; Hofmann WJ; Stremmel W; Theilmann L
    Z Gastroenterol; 1997 Apr; 35(4):255-61. PubMed ID: 9163889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transcriptome at the time of hepatitis C virus recurrence may predict the severity of fibrosis progression after liver transplantation.
    Mas V; Maluf D; Archer KJ; Potter A; Suh J; Gehrau R; Descalzi V; Villamil F
    Liver Transpl; 2011 Jul; 17(7):824-35. PubMed ID: 21618696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.